Network medicine might lead to new treatments for dyslipidemia. It will be a challenging method to implement in a clinical context

Abstract

With statin-based therapies to prevent or delay atherosclerotic progression, the reductionist approach of strict guidelines for treating dyslipidemias resulted in remarkable low-density lipoprotein transported cholesterol reduction. The precise estimation of residual cardiovascular diseases risk, on the other hand, remains a significant challenge that necessitates the development of new integrated approaches. The application of a network medicine approach could lead to the development of novel strategies. This is unquestionably a multidisciplinary strategy that will be difficult to put into practice in a clinical setting. We must dissect a patient with dyslipidemia to the level of single cell analysis and then reconstruct the puzzle to get a complete picture of nodes and disease modules. These efforts are critical for fully comprehending the molecular networks that underpin dyslipidemia and atherosclerosis. Furthermore, computer-aided decision-making is becoming more common in the clinical evaluation of subjects with suspected coronary heart disease. Physicians, on the other hand, should keep in mind that machines lack a "sense of reasoning" and should therefore question the reliability of a clinical decision made solely by robots. As a result, AI should be referred to as "augmented intelligence," which can aid physicians in decision-making but should leave the final strategy in their hands.